As of November 6, 2026, Marker Therapeutics, Inc. is a publicly traded company (Nasdaq: MRKR). The largest holder reporting an active stake on Schedule 13D is New Enterprise Associates 16, L.P., at 9.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Alyeska (9.9%) (Schedule 13D/A, November 17, 2025).
Is this your company?
About to sign with, pay or invest in Marker Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Marker Therapeutics, Inc. a real, registered company?
- Marker Therapeutics, Inc. files with the SEC under CIK 1094038 (its SEC filings).
- Its shares are listed under the ticker MRKR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Houston, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Marker Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names New Enterprise Associates 16, L.P. (filed 2025-11-17).
Who are Marker Therapeutics, Inc.'s owners and officers?
Marker Therapeutics, Inc.: incorporated in Delaware; business address in Houston, Texas; industry Pharmaceutical Preparations (Schedule 13D/A, 2025-11-17).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-12-30)
- : Director (Form D, 2024-12-30)
- : Director (Form D, 2024-12-30)
- : Director (Form D, 2024-12-30)
- : Director (Form D, 2024-12-30)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2025-11-17 | New Enterprise Associates 16, L.P. | 9.9% |
| Schedule 13G/A, 2025-11-14 | Alyeska Investment Group, L.P. | 9.9% |
| Schedule 13D/A, 2025-08-20 | John R. Wilson Tte, John R. Wilson Revocable Trust U/A Dtd 08/03/2017 | 4.96% |
| Schedule 13D/A, 2025-08-19 | John R. Wilson Tte, John R. Wilson Revocable Trust U/A Dtd 08/03/2017 | 5.1% |
| Schedule 13D/A, 2025-08-18 | New Enterprise Associates 16, L.P. | 12.6% |
Questions about who owns Marker Therapeutics, Inc.
Who owns Marker Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Marker Therapeutics, Inc.: New Enterprise Associates 16, L.P. (9.9%, Schedule 13D/A, filed 2025-11-17) and Alyeska Investment Group, L.P. (9.9%, Schedule 13G/A, filed 2025-11-14).
Who are the largest shareholders of Marker Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Marker Therapeutics, Inc. on this page are New Enterprise Associates 16, L.P. (9.9%) and Alyeska Investment Group, L.P. (9.9%).
When did New Enterprise Associates 16, L.P. buy into Marker Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from New Enterprise Associates 16, L.P. on this page is the Schedule 13D/A, filed 2025-08-18, reporting 12.6%; its latest, Schedule 13D/A filed 2025-11-17, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Marker Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Marker Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Marker Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Marker Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- NEA Partners 16, L.P., a 10% owner: 1,625,678 shares (9.8% of shares outstanding), on a joint filing (Form 4, 2024-12-23).
- , a 10% owner: 1,625,678 shares (9.8% of shares outstanding), on a joint filing (Form 4, 2024-12-23).
- , a 10% owner: 1,625,678 shares (9.8% of shares outstanding), on a joint filing (Form 4, 2024-12-23).
- Nea 16 GP, LLC, a 10% owner: 1,625,678 shares (9.8% of shares outstanding), on a joint filing (Form 4, 2024-12-23).
- , a 10% owner: 1,625,678 shares (9.8% of shares outstanding), on a joint filing (Form 4, 2024-12-23).
Shares outstanding: 16,673,127 as of 2026-08-07, from the company's latest SEC cover page.
How much has Marker Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-12-30 | $16.10M | $16.10M |
Keep reading
More on Marker Therapeutics, Inc. and the records around it.
Marker Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2025
Companies that share a holder
- New Enterprise Associates 16, L.P. also filed stake reports on 1 other company: Trevi Therapeutics, Inc. (May 2026)
- Alyeska Investment Group, L.P. also filed stake reports on 81 other companies: ABUNDIA GLOBAL IMPACT GROUP, INC. (Aug 2026), Bakkt, Inc. (Aug 2026), BATTALION OIL CORP (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/marker-therapeutics